Latest Publications

Share:

Proposed CMS Regulation Pushes Alignment Between Medicare Coverage and FDA Breakthrough Device Approvals

On August 31, 2020, the Centers for Medicare & Medicaid Services (CMS) proposed a rule to align Medicare coverage decisions with breakthrough technologies approved by the Food and Drug Administration (FDA), thereby speeding...more

FDA Updates: ‘Conduct of Clinical Trials’ During the COVID-19 Emergency Receives Timely Clarifications and Important Additional...

On May 14, 2020, the U.S. Food and Drug Administration (FDA) updated its FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency – Guidance for Industry, Investigators, and...more

Another Step in Expanding Personal Protective Equipment: FDA Extends EUA to Face Shields

The Food and Drug Administration (FDA) issued on April 9, 2020 its first emergency use authorization (EUA) for face shields to address the significant shortage of personal protective equipment (PPE) during the COVID-19...more

Responses to the Current Ventilator Shortage: FDA’s Recommendations and Guidance for Industry and Health Care Providers

The Society of Critical Care Medicine estimates that the United States has over 200,000 ventilators, although other organizations have lower estimates. ...more

FDA Touts Results of New Prosecutorial Enforcement Muscle Worldwide

The Food and Drug Administration (FDA) is increasing and strengthening its ability to enforce criminal sanctions against conduct related to illegal FDA-regulated products across the globe, according to an October...more

Beware Billing Medicare for Non-Approved Imported Drugs

Dr. Mark Fleckner, a board-certified New York ophthalmologist, will pay almost $7 million to settle civil fraud claims arising from giving patients imported macular degeneration drugs that had not been evaluated or approved...more

If You Think You’re Safe from FDA Scrutiny Because You’re in an Ivory Tower, Think Again

FDA increases enforcement based on clinical research violations. According to recently-posted data, 2014 was a banner year for FDA enforcement based on clinical research violations. ...more

7 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide